{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:17:50Z","timestamp":1790734670887,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1803,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["NCT00094302"],"award-info":[{"award-number":["NCT00094302"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["NCT00094302"],"award-info":[{"award-number":["NCT00094302"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Diabetes mellitus (DM) is common in heart failure with preserved ejection fraction (HFpEF). Patients with DM and heart failure with reduced ejection fraction have higher levels of cardiac, profibrotic, and proinflammatory biomarkers relative to non-diabetics. Limited data are available regarding the biomarker profiles of HFpEF patients with diabetes (DM) vs. no diabetes (non-DM) and the impact of spironolactone on these biomarkers. This study aims to address such gaps in the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Biomarkers were measured at randomization and at 12 months in 248 patients enrolled in Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist's North American cohort. At baseline, DM patients had significantly lower estimated glomerular filtration rate and higher high-sensitivity C-reactive protein, pro-collagen type III amino-terminal peptide, tissue inhibitor of metalloproteinase 1 (TIMP-1), and galectin-3 levels than those without diabetes. There was a significantly larger 12 month increase in levels of high-sensitivity troponin T (hs-TnT), a marker of myocyte death, in DM patients. Elevated pro-collagen type III amino-terminal peptide and galectin-3 levels were associated with an increased risk of the primary outcome (cardiovascular mortality, aborted cardiac arrest, or heart failure hospitalization) in DM patients, but not in those without diabetes. A statistically significant interaction between spironolactone and diabetes status was observed for hs-TnT and for TIMP-1, with greater biomarker reductions among those with diabetes treated with spironolactone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The presence of diabetes is associated with higher levels of cardiac, profibrotic, and proinflammatory biomarkers in HFpEF. Spironolactone appears to alter the determinants of extracellular matrix remodelling in an anti-fibrotic fashion in patients with diabetes, reflected by changes in hs-TnT and TIMP-1 levels over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13153","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T05:51:36Z","timestamp":1610689896000},"page":"1130-1138","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Impact of Diabetes on Serum Biomarkers in Heart Failure with Preserved Ejection Fraction: Insights from the TOPCAT Trial"],"prefix":"10.1093","volume":"8","author":[{"given":"Corrado","family":"De Marco","sequence":"first","affiliation":[{"name":"Division of Cardiology, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , 5000 rue B\u00e9langer, Montreal, QC, H1T 1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"de Denus","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , 5000 rue B\u00e9langer, Montreal, QC, H1T 1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Huynh","sequence":"additional","affiliation":[{"name":"McGill University Health Centre and McGill University , Montreal, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Sirois","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , 5000 rue B\u00e9langer, Montreal, QC, H1T 1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , 5000 rue B\u00e9langer, Montreal, QC, H1T 1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O'Meara","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , 5000 rue B\u00e9langer, Montreal, QC, H1T 1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"2026012115072777900_ehf213153-bib-0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012115072777900_ehf213153-bib-0002","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012115072777900_ehf213153-bib-0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012115072777900_ehf213153-bib-0004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012115072777900_ehf213153-bib-0005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012115072777900_ehf213153-bib-0006","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"2026012115072777900_ehf213153-bib-0007","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"2026012115072777900_ehf213153-bib-0008","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"2026012115072777900_ehf213153-bib-0009","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/ejhf.912","article-title":"A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure","volume":"19","author":"Sharma","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115072777900_ehf213153-bib-0010","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/CIRCULATIONAHA.115.015744","article-title":"Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia","volume":"132","author":"Gerstein","year":"2015","journal-title":"Circulation"},{"key":"2026012115072777900_ehf213153-bib-0011","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"100","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"2026012115072777900_ehf213153-bib-0012","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12933-016-0470-x","article-title":"Impact of diabetes on the predictive value of heart failure biomarkers","volume":"15","author":"Alonso","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"2026012115072777900_ehf213153-bib-0013","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","article-title":"Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-PRESERVE trial (Irbesartan in Heart Failure with Preserved Ejection Fraction)","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"2026012115072777900_ehf213153-bib-0014","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"2026012115072777900_ehf213153-bib-0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115072777900_ehf213153-bib-0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026012115072777900_ehf213153-bib-0017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026012115072777900_ehf213153-bib-0018","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012115072777900_ehf213153-bib-0019","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurjhf\/hfn036","article-title":"Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover","volume":"11","author":"Martos","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026012115072777900_ehf213153-bib-0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026012115072777900_ehf213153-bib-0021","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012115072777900_ehf213153-bib-0022","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00592-018-1142-y","article-title":"Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes","volume":"55","author":"Giorda","year":"2018","journal-title":"Acta Diabetol"},{"key":"2026012115072777900_ehf213153-bib-0023","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012115072777900_ehf213153-bib-0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005312","article-title":"Cardiac troponin I and risk of cardiac events in patients with heart failure and preserved ejection fraction","volume":"11","author":"Myhre","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012115072777900_ehf213153-bib-0025","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1093\/eurheartj\/ehx510","article-title":"Fibrosis as measured by the biomarker, tissue inhibitor mettaloproteinase-1, predicts mortality in Age Gene Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study","volume":"38","author":"LaRocca","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012115072777900_ehf213153-bib-0026","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ehj.2004.05.029","article-title":"Relation of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study","volume":"25","author":"S\u00fcndstrom","year":"2004","journal-title":"Eur Heart J"},{"key":"2026012115072777900_ehf213153-bib-0027","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"2026012115072777900_ehf213153-bib-0028","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/eurjhf\/hfr151","article-title":"Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial","volume":"14","author":"Lopez-Andr\u00e8s","year":"2012","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13153","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13153","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1130\/65926393\/eschf_8_2_1130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1130\/65926393\/eschf_8_2_1130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:09:17Z","timestamp":1769026157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/2\/1130\/8381845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,12]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13153","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"2020-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}